PH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 1, 2013, Pages 81-89

  Balogh, György T ^a   Müller, Judit ^b   Könczöl, Árpád ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Drug induced phospholipidosis; Noncell based model; One way transport model from cytosol to lysosome; pH gradient PAMPA; Tissue specificity

Indexed keywords

AMFEBUTAMONE; AMPHOPHILE; CATIONIC AMPHIPHILIC DRUG; PHENACETIN; UNCLASSIFIED DRUG; DRUG; PHOSPHOLIPID;

ARTICLE; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; CYTOSOL; DRUG METABOLISM; HIGH THROUGHPUT IN VITRO PERMEABILITY MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID ANALYSIS; LIPIDOSIS; LYSOSOME; MODEL; NONHUMAN; PERMEABILITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; METABOLISM;

DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HYDROGEN-ION CONCENTRATION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS;

EID: 84874941955     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.02.005     Document Type: Article

References (55)

1. N. Anderson, and J. Borlak Drug-induced phospholipidosis FEBS Lett. 580 2006 5533 5540 (Pubitemid 44465910)
2. J.M. Antonini, and M.J. Reasor Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture Biochem. Pharmacol. 42 Suppl 1991 S151 156
3. P. Artursson, K. Palm, and K. Luthman Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Deliv. Rev. 46 2001 27 43
4. A. Avdeef Chimia 57 2003 61
5. Avdeef, A., 2003b. Absorption and Drug Development Solubility, Permeability and Charge State. pION, Inc. John Wiley & Sons, pp. 116-152.
6. Avdeef, A., 2003c. Absorption and Drug Development Solubility, Permeability and Charge State. pION, Inc. John Wiley & Sons.
7. A. Avdeef, M. Kansy, S. Bendels, and K. Tsinman Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 33 2008 29 41 (Pubitemid 350235188)
8. A.P. Beresford, D. McGibney, M.J. Humphrey, P.V. Macrae, and D.A. Stopher Metabolism and kinetics of amlodipine in man Xenobiotica Fate Foreign Compounds Biol. Syst. 18 1988 245 254 (Pubitemid 18071751)
9. Berridge, B.R., Chatman, L.A., Odin, M., Schultze, A.E., Losco, P.E., Meehan, J.T., Peters, T., Vonderfecht, S.L., Society of Toxicologic Pathology, S., Regulatory Policy Committee Working, G., 2007. Phospholipidosis in nonclinical toxicity studies. Tox. Path. 35, 325.
10. A. Casartelli, M. Bonato, P. Cristofori, F. Crivellente, G. Dal Negro, I. Masotto, C. Mutinelli, K. Valko, and V. Bonfante A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development Cell Biol. Toxicol. 19 2003 161 176 (Pubitemid 36975596)
11. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232 (Pubitemid 36349665)
12. Fischer, H., Kansy, M., Potthast, M., Csato, M., 1998. Rational Approaches to Drug Design. In: Proceedings of the 13th European Symposium on Quantitative Structure-Activity Relationships. Prous Science, Barcelona.
13. R.J. Gum, D. Hickman, J.A. Fagerland, M.A. Heindel, G.D. Gagne, J.M. Schmidt, M.R. Michaelides, S.K. Davidsen, and R.G. Ulrich Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1) Biochem. Pharmacol. 62 2001 1661 1673 (Pubitemid 34033653)
14. W.H. Halliwell Cationic amphiphilic drug-induced phospholipidosis Toxicol. Pathol. 25 1997 53 60 (Pubitemid 27100559)
15. U.M. Hanumegowda, G. Wenke, A. Regueiro-Ren, R. Yordanova, J.P. Corradi, and S.P. Adams Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds Chem. Res. Toxicol. 23 2010 749 755
16. L. Hein, R. Lullmann-Rauch, and K. Mohr Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis Xenobiotica Fate Foreign Compounds Biol. Syst. 20 1990 1259 1267
17. Z. Jiang, and J. Reilly Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals J. Pharm. Biomed. Anal. 61 2012 184 190
18. U.M. Joshi, P. Rao, S. Kodavanti, V.G. Lockard, and H.M. Mehendale Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis Biochim. Biophys. Acta 1004 1989 309 320 (Pubitemid 19216469)
19. S. Kacew, R. Narbaitz, J.A. Ruddick, and D.C. Villeneuve Role of drug metabolism in protection against chlorphentermine-induced pulmonary phospholipidosis in adult rat Exp. Mol. Pathol. 35 1981 98 107 (Pubitemid 11035609)
20. R.C. Kammerer, and D.A. Schmitz A comparative in vitro metabolic study of methaphenilene and pyribenzamine Xenobiotica Fate Foreign Compounds Biol. Syst. 18 1988 1085 1096
21. M. Kansy, A. Avdeef, and H. Fischer Advances in screenincg formembrane permeability: high-resolution PAMPA for medicinal chemists Drug Discovery Today Technol. 1 2004 349 355 (Pubitemid 40186337)
22. M. Kansy, F. Senner, and K. Gubernator Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 41 1998 1007 1010 (Pubitemid 28207375)
23. D.W. Kelly, C.L. Holder, W.A. Korfmacher, T.A. Getek, J.O. Lay Jr., D.A. Casciano, J.G. Shaddock, H.M. Duhart, and W. Slikker Jr. Metabolism of methapyrilene by Fischer-344 rat and B6C3F1 mouse hepatocytes Xenobiotica Fate Foreign Compounds Biol. Syst. 22 1992 1367 1381 (Pubitemid 23017643)
24. K.A. Kim, J.Y. Park, J.S. Lee, and S. Lim Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes Arch. Pharmacal Res. 26 2003 631 637 (Pubitemid 43080195)
25. U.P. Kodavanti, and H.M. Mehendale Cationic amphiphilic drugs and phospholipid storage disorder Pharmacol. Rev. 42 1990 327 354
26. U.P. Kodavanti, and H.M. Mehendale Amiodarone- and desethylamiodarone- induced pulmonary phospholipidosis, inhibition of phospholipases in vivo, and alteration of [14C]amiodarone uptake by perfused lung Am. J. Respir. Cell Mol. Biol. 4 1991 369 378
27. S. Kudo, K. Umehara, M. Hosokawa, G. Miyamoto, K. Chiba, and T. Satoh Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation J. Pharmacol Exp Therap. 294 2000 80 88
28. H. Lullmann, R. Lullmann-Rauch, and O. Wassermann Lipidosis induced by amphiphilic cationic drugs Biochem. Pharmacol. 27 1978 1103 1108 (Pubitemid 8393243)
29. J.C. Molnari, H.E. Hassan, and A.L. Myers Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice Eur. J. Drug Metab. Pharmacokinet. 37 2012 57 63
30. J.K. Morelli, M. Buehrle, F. Pognan, L.R. Barone, W. Fieles, and P.J. Ciaccio Validation of an in vitro screen for phospholipidosis using a high-content biology platform Cell Biol. Toxicol. 22 2006 15 27 (Pubitemid 43207806)
31. M. Nakamura, T. Onodera, and T. Akino Characteristics of phospholipids in human lung carcinoma Lipids 15 1980 616 623 (Pubitemid 11208324)
32. A.A. Nelson, and O.G. Fitzhugh Chloroquine (SN-7618) pathologic changes observed in rats which for 2 years had been fed various proportions Arch. Pathol. 45 1948 454 462
33. D.J. Pelletier, D. Gehlhaar, A. Tilloy-Ellul, T.O. Johnson, and N. Greene Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J. Chem. Inf. Model. 47 2007 1196 1205 (Pubitemid 46973733)
34. A. Peropadre, P. Fernandez Freire, O. Herrero, J.M. Perez Martin, and M.J. Hazen Cellular responses associated with dibucaine-induced phospholipidosis Chem. Res. Toxicol. 24 2011 185 192
35. a and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines Exp Tox. Path: Off. J. Gesellschaft fur Toxikologische Pathologie 55 2004 347 355 (Pubitemid 38425469)
36. A.J. Ratcliffe Medicinal chemistry strategies to minimize phospholipidosis Curr. Med. Chem. 16 2009 2816 2823
37. M.J. Reasor A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs Toxicol. Appl. Pharmacol. 97 1989 47 56 (Pubitemid 19054592)
38. M.J. Reasor, and S. Kacew Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 226 2001 825 830 (Pubitemid 34053231)
39. R.J. Riley, P. Roberts, N.R. Kitteringham, and B.K. Park Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes Biochem. Pharmacol. 39 1990 1951 1958 (Pubitemid 20187331)
40. J.K. Seydel, M. Wiese, H.P. Cordes, and H.L. Chi QSAR and multivariate data analysis of the interaction of amphiphilic drugs with phospholipids Prog. Clin. Biol. Res. 291 1989 117 122
41. P.A. Shore, B.B. Brodie, and C.A. Hogben The gastric secretion of drugs: a pH partition hypothesis J. Pharmacol Exp. Ther. 119 1957 361 369
42. B. Sinko, T.M. Garrigues, G.T. Balogh, Z.K. Nagy, O. Tsinman, A. Avdeef, and K. Takacs-Novak Skin-PAMPA: a new method for fast prediction of skin penetration Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 45 2012 698 707
43. K. Sugano, H. Hamada, M. Machida, and H. Ushio High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay J. Biomol. Screen. 6 2001 189 196 (Pubitemid 32554136)
44. K. Sugano, H. Hamada, M. Machida, H. Ushio, K. Saitoh, and K. Terada Optimized conditions of bio-mimetic artificial membrane permeation assay Int. J. Pharm. 228 2001 181 188 (Pubitemid 32905377)
45. K. Tomizawa, K. Sugano, H. Yamada, and I. Horii Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential J. Tox. Sci. 31 2006 315 324 (Pubitemid 44730413)
46. L.M. Tremaine, W.M. Welch, and R.A. Ronfeld Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog Drug Metab. Dispos: Biol Fate Chem. 17 1989 542 550 (Pubitemid 19244919)
47. O. Tsinman, K. Tsinman, N. Sun, and A. Avdeef Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model Pharm. Res. 28 2011 337 363
48. R.G. Ulrich, K.S. Kilgore, E.L. Sun, G.T. Cramer, and L.C. Ginsberg An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies Toxicol. Methods 1 1991 89 105
49. M. Velicky, D.F. Bradley, K.Y. Tam, and R.A. Dryfe In situ artificial membrane permeation assay under hydrodynamic control: permeability-pH profiles of warfarin and verapamil Pharm. Res. 27 2010 1644 1658
50. P. Vitovic, J.M. Alakoskela, and P.K. Kinnunen Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis J. Med. Chem. 51 2008 1842 1848 (Pubitemid 351444629)
51. Y. Watanabe, K. Watanabe, I. Tashiro, and Y. Enomoto The twenty-seventh scientific meeting of the japanese society of electron microscopy J. Electron Microsc. 20 1971 49 99
52. F. Wohnsland, and B. Faller High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes J. Med. Chem. 44 2001 923 930 (Pubitemid 32861617)
53. W. Yamanaka, and R. Ostwald Lipid composition of heart, kidney and lung in guinea pigs made anemic by dietary cholesterol J. Nutr. 95 1968 381 387
54. K.A. Youdim, A. Avdeef, and N.J. Abbott In vitro trans-monolayer permeability calculations: often forgotten assumptions Drug Discovery Today 8 2003 997 1003 (Pubitemid 37468418)
55. Zhou L. Geraci G. Hess S. Yang L. Wang J. Argikar U. Predicting phospholipidosis: A fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery Anal. Chem. 2011 83 6980-6987.